Drug Giant Pfizer Begins Testing Experimental COVID-19 Vaccine On ‘Young And Healthy’ Volunteers, Promises 20 Million Doses January

New post on Now The End Begins

Drug Giant Pfizer Begins Testing Experimental COVID-19 Vaccine On ‘Young And Healthy’ Volunteers, Promises 20 Million Doses January by Geoffrey Grider Pfizer has begun dosing Americans with its experimental coronavirus vaccines for its clinical trial in collaboration with BioNTech SE, the pharmaceutical giant announced Tuesday. I spent the first half of my 20-plus year career as a graphic artist working for some of the biggest pharmaceutical companies in the world, never worked for Pfizer though. But I know how they operate, and how they think, and how they will spare no expense to cut any corner to squeeze as much money as possible out of the sale of their medicines. Those sappy, tear-jerking commercials they play on television bear little to no resemblance to the cutthroat world of Big Pharma new product development. Their bottom line will always be money. So now we have our first tentative timeline for when we can expect COVID-19 vaccinations to begin, the end of 2020. Let me warn you now not to be confused when it doesn't appear to be tied to Bill Gates and the WHO right away, the first few rounds will be disarming. Everyone will be so optimistic and cheerful, but don't let that fool you. The vaccinations will have many stages before the final launch, and you need to make up your mind now, right now, as to whether or not you will allow them, whomever "they" will be, to inject you with poison and perdition. Speaking of marketing, I put some Pfizer videos at the bottom, watch and decide for yourself who's telling you the truth. Pfizer gives first doses of experimental vaccine to 'young and healthy' Americans - and promises 20 million doses by the end of the year FROM DAILY MAIL UK: The US drug maker Pfizer and German partner BioNTech SE said if the vaccine proves to be safe and effective in trials, it could potentially be ready for wide US distribution by the end of the year, shaving several years off the typical vaccine development timeline. The vaccine, which uses messenger RNA (mRNA) technology, has the potential to be among the first vaccines against the virus that has infected more than 1 million people in the United States and killed some 68,000. FOR THOSE OF YOU WHO TAKE THE VACCINE JUST REMEMBER IT WILL COME WITH A DIGITAL ID CALLED THE IMMUNITY PASSPORT Pfizer joined the race to make a coronavirus vaccine late, but hopes that with its trial in 360 healthy volunteers, it can speed ahead and have more than 20 million doses ready by year-end - if the shot proves safe. There are currently no approved treatments or vaccines for the new coronavirus, though some drugs are being used on patients under an emergency use authorization. The US study is part of a broader, global program already underway in Germany, where BioNTech is based. Dosing there began last month. Moderna Inc is using similar technology for its vaccine being developed along with the US government. Phase I testing of that vaccine candidate has also begun, with mid-stage trials planned in the current quarter. Pfizer said last week it hopes to receive emergency authorization from the US Food and Drug Administration (FDA) as early as October, and could distribute up to 20 million doses by the end of 2020, with an eye toward producing hundreds of millions of doses next year. 'Even going from a few million to 20 million will allow you to protect the epicenters of the virus, and then drive out the virus from our society as we ramp up to hundreds of millions,' Pfizer research chief Mikael Dolsten told Reuters in an interview. Using synthetic mRNA technology can enable the vaccine to be developed and manufactured more quickly than traditional vaccines, the companies said. Pfizer said last week it expects to make safety data on the vaccine available by late May. The trial will initially aim to test different dosing regimens of four potential vaccine candidates on around 360 healthy volunteers divided into a younger cohort and a group of seniors. The trial will expand to more subjects after researchers determine which compounds and dosing regimens are most effective, said Kirsten Lyke, a director at the University of Maryland's Center for Vaccine Development and Global Health, which is participating in the trial. READ MORE